HOME >> MEDICINE >> NEWS
Pitt's transplant team uses standard stem cell procedure in unique way for recipient of living donor kidney transplant

Boost of brother's immune system cells could mean drug-free kidney transplant for sister

PITTSBURGH, Feb. 4 A grateful sister got more than her brother's kidney; she also got millions of cells from his immune system in a procedure that transplant surgeons at the University of Pittsburgh's Thomas E. Starzl Transplantation Institute, working with the University of Pittsburgh Cancer Institute, hope will allow her eventual freedom from all anti-rejection drugs.

The technique, called peripheral blood stem cell transplantation, is standard for patients with certain types of cancers, but in what is believed to be a first, it was tried in a non-cancer patient receiving a kidney from a living donor as a means to induce drug-free tolerance of the transplanted organ.

On Jan. 11, a 54-year-old woman received a kidney donated by her 47-year-old brother. Three days later, in a simple bedside procedure taking less than 20 minutes, the woman also received an infusion of her brother's immune system cells taken from blood he had donated during a four-hour outpatient session this past month. Both donor and recipient were discharged five days after transplant.

"So far, we are pleased with how the donor and recipient are doing. By all indications, the recipient's transplanted kidney is functioning well, and she has had no complications from the stem cell infusion. But it is too soon to know if the stem cell infusion will be effective. It will be several months or more before we'll determine whether it is safe to begin weaning her off immunosuppressive drugs," said the recipient's surgeon, Velma Scantlebury, M.D., associate professor of surgery at the Thomas E. Starzl Transplantation Institute.

"Unlike liver transplant patients, very few kidney recipients have been able to be safely weaned off immunosuppression. We think this is because the kidney contains less of the types of cells that are immunoprotective. It is presumed tha
'"/>

Contact: Lisa Rossi
412-647-3555
University of Pittsburgh Medical Center
4-Feb-2002


Page: 1 2 3

Related medicine news :

1. Success of liver transplantation may be most influenced by three risk factors
2. Alcohol relapse adversely affects 10-year liver transplant survival
3. Donor age has no affect on long-term liver transplant survival
4. Age shouldnt be a factor in kidney transplantation
5. Cornea transplants can be improved
6. Investigational transplant drug effectively preserves kidneys while avoiding toxic side effects
7. Hard choices: Pitt researcher presents findings on when to accept organ transplants
8. Biochemical marker aids prognosis in liver transplant patients
9. Single-donor islet transplantation procedure shows promise for patients with type 1 diabetes
10. Age should not be a factor in determining heart transplantation eligibility, researchers say
11. Study explores risks of obesity in children with kidney transplants

Post Your Comments:
(Date:5/22/2013)... CoCENTRIX, a leading provider of coordinated ... Services and community providers, announced today that the ... CoCENTRIX Coordinated Care Platform (CoCENTRIXccp) as ... and coordinate care within and amongst its four ... transitioning the hospitals' official records from paper-based to ...
(Date:5/22/2013)... Denver, CO (PRWEB) May 22, 2013 ... of legal discovery management services for law firms, corporations ... Cumulus Data, Inc., a cloud-based e-discovery software company, to ... of this newly formed partnership, Cumulus Data and LDM ... Standard, downtown LA on Tuesday, May 21st. This ...
(Date:5/22/2013)... 2013 BroadConnect Telecom, the leading ... security solutions in North America announced plans to ... newest BroadConnect hosted security solutions. Available on premise, ... BroadConnect’s new Security as a Service (SaaS) enables ... connection of their choice, while optimizing internal network ...
(Date:5/22/2013)... Poor adherence to appropriate medication therapy has ... and death (some 125,000 deaths in the U.S. every ... costs. It’s been estimated that between 33% and 69% ... medication adherence — a reality that costs the American ... dire is the degree of medication non-adherence — and ...
(Date:5/22/2013)... Dallas, TX (PRWEB) May 22, 2013 Mari’s ... in Dallas, has become the first in the state of ... is called Meta Therapy- Medical and Esthetic Tissue Activation, also ... used for over four years in Europe, but has just ... Meta Therapy improves the skin from inside out by building ...
Breaking Medicine News(10 mins):Health News:The State of Alabama Selects the CoCENTRIX Coordinated Care Platform to Facilitate Care for Its Citizens Treated in State Psychiatric Hospitals 2Health News:The State of Alabama Selects the CoCENTRIX Coordinated Care Platform to Facilitate Care for Its Citizens Treated in State Psychiatric Hospitals 3Health News:LDM Global Enhances Forensic Data Collection Services with eCloudCollect 2Health News:LDM Global Enhances Forensic Data Collection Services with eCloudCollect 3Health News:BroadConnect Telecom to Launch Enterprise-Grade Hosted Security Solutions Engineered to Meet the Demands of Real World Business 2Health News:Patient Prompt® Announces New Drug Adherence Program to Assist in Prescribed Medication Compliance 2Health News:Mari's to Offer New Treatment from Europe 2
(Date:5/22/2013)... , May 22, 2013  Grifols, a global ... , presented results from a study demonstrating that a ... Inhibitor [Human]) increased levels of the alpha 1 ... to levels that are considered within the normal range ... condition in which low levels of the alpha 1 ...
(Date:5/22/2013)... , May 22, 2013  BD (Becton, Dickinson ... global medical technology company, announced today the publication of ... fifth Sustainability Report and it continues to focus on ... "We believe the principles of shared value — ... healthcare challenges of societies — are fundamental to our ...
(Date:5/22/2013)... , May 22, 2013 Rigel Pharmaceuticals, Inc. ... advancement of three programs in development. The first program ... inhibitor, R348, being developed by Rigel as a treatment ... aimed at oncology targets and are being conducted by ... by BerGenBio AS (BerGenBio) and a ligase inhibitor under ...
Breaking Medicine Technology:Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 2Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 3Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 4BD Issues 2012 Sustainability Report 2BD Issues 2012 Sustainability Report 3Rigel's R348 to Initiate Phase 2 Clinical Trial in Dry Eye 2Rigel's R348 to Initiate Phase 2 Clinical Trial in Dry Eye 3Rigel's R348 to Initiate Phase 2 Clinical Trial in Dry Eye 4
Cached News: